As the public health crisis fuels an economic one, more and more companies find themselves on the brink. Corporate crises bring a barrage of questions. Employees worry about their jobs. Shareholders worry about their investments. Regulators ask whether the company was prepared. And everyone wants to know the plan. The questions are many, and tough.

I joined Theranos to help answer them. I became its general counsel in late 2016, in the midst of a crisis over the company’s blood-testing technology. Media exposés had prompted investor outrage, government investigations and hundreds of millions of dollars in lawsuits.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]